Table 3 Predictability of efficacy endpoints for an HBV DNA reduction threshold of ≤5 log ₁₀ copies/mL vs. >5 log ₁₀ copies/mL at Week 24

Treatment Year 1

Maintained PCR negativity

0.650

(0.119, 3.541)

0.6183

Maintained ALT normalization

0.283

(0.032, 2.530)

0.2586

Maintained HBeAg loss

0.000

(0.000, >999.9)

0.9619

Maintained HBeAg seroconversion

0.000

(0.000, >999.9)

0.9517

Treatment Year 2

Maintained PCR negativity

0.075

(0.007, 0.765)

0.0288

Maintained ALT normalization

0.349

(0.056, 2.174)

0.2592

Maintained HBeAg loss

0.339

(0.032, 3.616)

0.3707

Maintained HBeAg seroconversion

0.368

(0.033, 4.085)

0.4156

Cumulative treatment-emergent resistance

9.593

(1.387, 66.347)

0.0219

Treatment Year 3

Maintained PCR negativity

0.056

(0.005, 0.623)

0.0190

Maintained ALT normalization

0.313

(0.053, 1.855)

0.2010

Maintained HBeAg loss

0.124

(0.012, 1.300)

0.0816

Maintained HBeAg seroconversion

0.313

(0.030, 3.231)

0.3295

Cumulative treatment-emergent resistance

>999.9

(0.000, >999.9)

0.9681

Treatment Year 4

Maintained PCR negativity

0.053

(0.005, 0.584)

0.0164

Maintained ALT normalization

0.195

(0.032, 1.1980

0.0776

Maintained HBeAg loss

0.147

(0.015, 1.4530

0.1009

Maintained HBeAg seroconversion

0.219

(0.022, 2.209)

0.1976

Cumulative treatment-emergent resistance

>999.9

(0.000, >999.9)

0.9681